文献速递生殖医学

随机临床试验:低剂量氟他胺对正常体重多囊卵巢综合征女性腹部脂肪生成功能的影响

Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
PubMed 文献 · Fertil Steril · 2022-11-15

双盲安慰剂对照随机临床试验纳入12例正常体重多囊卵巢综合征(PCOS)女性和12例年龄及体重指数匹配的对照,PCOS女性接受6个月氟他胺125 mg口服每日一次或安慰剂。氟他胺较安慰剂降低安卓脂肪百分比、降低血清对数低密度脂蛋白和非高密度脂蛋白水平、升高空腹血糖,并减弱体外新形成皮下腹部脂肪细胞脂质蓄积。

要点

  • PCOS女性血清黄体生成素、雄激素水平及新形成皮下腹部脂肪细胞脂质蓄积高于对照。
  • 氟他胺较安慰剂降低安卓脂肪百分比,降低血清对数低密度脂蛋白和非高密度脂蛋白水平。
  • 氟他胺较安慰剂升高空腹血糖,并减弱体外新形成PCOS皮下腹部脂肪细胞脂质蓄积。

核心结论

  • 正常体重PCOS女性使用低剂量氟他胺可减少 preferential 腹部脂肪沉积,减弱体外新形成皮下腹部脂肪干细胞来源脂肪细胞的加速脂质蓄积,并改变糖脂稳态。

研究设计与样本

  • 双盲、安慰剂对照随机临床试验,在学术医疗中心进行;12例正常体重PCOS女性和12例年龄及体重指数匹配的对照。
  • PCOS女性在6个月氟他胺125 mg口服每日一次或安慰剂给药前后重复激素代谢测定、静脉葡萄糖耐量试验、全身双能X线吸收测定和皮下腹部脂肪活检。

主要发现

  • PCOS女性血清黄体生成素和雄激素水平以及新形成皮下腹部脂肪细胞脂质蓄积高于对照。
  • 氟他胺较安慰剂降低安卓脂肪百分比,降低血清对数低密度脂蛋白和血清对数非高密度脂蛋白水平,并升高空腹循环血糖水平。
  • 所有PCOS女性中,安卓脂肪百分比变化与血清对数非高密度脂蛋白和对数低密度脂蛋白水平正相关,相关性受血清游离睾酮水平影响。
  • 氟他胺较安慰剂还减弱体外新形成PCOS皮下腹部脂肪细胞脂质蓄积(相对于对照),且与血清脂质水平无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether low-dose flutamide administration to normal-weight women with polycystic ovary syndrome (PCOS) reduces abdominal fat deposition, attenuates accelerated lipid accumulation in newly formed adipocytes derived from subcutaneous (SC) abdominal adipose stem cells (ASCs), and/or alters glucose-lipid metabolism. DESIGN: A double-blind, placebo-controlled randomized clinical trial. SETTING: An academic medical center. PATIENT(S): Twelve normal-weight women with PCOS and 12 age- and body mass index-matched controls. INTERVENTION(S): Women underwent circulating hormonal and metabolic determinations, intravenous glucose tolerance testing, total body dual-energy roentgenogram absorptiometry, and SC abdominal fat biopsy. Interventions were repeated in women with PCOS after 6-month administration of flutamide (125 mg orally daily) vs. placebo. MAIN OUTCOME MEASURE(S): Clinical parameters and lipid accumulation in newly formed adipocytes derived from SC abdominal ASCs in vitro were compared between controls and the women with PCOS receiving flutamide vs. placebo. RESULTS: Serum luteinizing hormone and androgen levels as well as lipid accumulation in newly formed SC abdominal adipocytes were greater in the women with PCOS than controls. Flutamide vs. placebo reduced percent android fat, lowered serum log low-density lipoprotein and log non-high-density lipoprotein levels, and increased fasting circulating glucose levels. In all women with PCOS, changes in percent android fat positively correlated with serum log non-high-density lipoprotein and log low-density lipoprotein levels, with correlations influenced by serum free testosterone levels. Flutamide vs. placebo also attenuated lipid accumulation in newly-formed PCOS SC abdominal adipocytes in vitro relative to controls, which was unrelated to serum lipid levels. CONCLUSION: Low-dose flutamide administration to normal-weight PCOS women reduces preferential abdominal fat deposition, attenuates accelerated lipid accumulation in newly-formed adipocytes derived from SC abdominal ASCs in vitro, and alters glucose-lipid homeostasis. CLINICAL TRIAL REGISTRATION NUMBER: NCT01889199 (URL, clinicaltrials.gov; date of registration, 6/28/2013; enrollment date of first subject, 6/28/2013).

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Dumesic DA, Winnett C, Lu G, et al. Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome. Fertil Steril. 2022. PMID: 36400597. doi:10.1016/j.fertnstert.2022.09.324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。